 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...3031323334353637383940...7475» |
- | Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi
Trial completion, Trial completion date: ZEBRA: Ziv-aflibercept Efficacy in Better Regulating AMD (clinicaltrials.gov) - Oct 5, 2020
P2, N=62, Completed, Sponsor: Kapil Kapoor
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Randomized Trial of Monthly versus As-needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1 Year Outcomes. (Pubmed Central) - Oct 4, 2020
Ranibizumab may improve vision and anatomy in patients with radiation retinopathy-related macular edema and prevent vision loss through 48 weeks of therapy. Monthly injections were more effective than as-needed approach, and the addition of TRP yielded no therapeutic benefits.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Oct 4, 2020
The mean decrease of mPEDH and cPEDH at the last follow-up after switching was significantly larger in the IVR subgroup than in the IVB subgroup (p=0.023 and 0.010). Our results indicate that switching from intravitreal conbercept injections to bevacizumab or ranibizumab can lead to significant improvement of CMT, PED, and IRF and slight improvement of BCVA in a short period of time for persistent nAMD patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intravitreal Therapies Pattern of Use in Italy- A Real-World Evidence Study on Maculopathies () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1462;
56 eyes treated for a 24-month time horizon, were administered with 5.52±0.36(range:1-6) ranibizumab injections. CONCLUSIONS : The study highlights differences between clinical practice and prescribing information, in terms of intravitreal injections frequency, suggesting the need to further analyze and describe reasons and related organizational factors and potential problems.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Patterns of Intravitreal Drug Prescription and Healthcare Costs for Patients Affected By Diabetic Macular Edema, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy or Myopic Choroidal Neovascularization () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1116;
This real-world study highlighted a decrease of anti-VEGF drugs prescriptions during follow-up. Our findings could indicate an inappropriate prescribing tendency that could increase the overall burden of ophthalmic diseases.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Cost Comparison of Licensed Intravitreal Therapies for Diabetic Macular Edema That Responds Insufficiently to Initial Intravitreal ANTI-VEGF in 2020 - a German 3 Year Cost MODEL () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_552;
In summary, the 3-year cost-cost comparison demonstrates that steroidal implants can provide significant cost savings versus intravitreal anti-VEGF treatment for center-involving DME. Single application of the long-lasting FAc implant was most cost-efficient of the intravitreal injections therapies currently approved for DME.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Network Meta-Analysis for Comparative Efficacy and Safety of ANTI-Vascular Endothelial Growth Factors in Diabetic Macular Oedema () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_369;
CONCLUSIONS : Aflibercept was more effective in improving visual acuity in DMO as compared to other anti-VEGFs. However, no difference in overall safety between the four monotherapies was observed.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Real-World Analysis of the Pharmaco-Utilization of Intravitreal Vascular Endothelial Growth Factor (VEGF) Inhibitors and Healthcare Costs Among Patients with WET Age-Related Macular Degeneration (WAMD) in Italy () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_293;
CONCLUSIONS. VEGF inhibitors prescriptions were observed to decrease over time, suggesting a trend of under-treatment among wAMD-patients analysed that could ultimately lead to the worsening of clinical outcomes and higher consumption of healthcare resources.
- [VIRTUAL] Budget IMPACT MODEL of the Dexamethasone Intravitreal Implant in Applicator () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_84;
The resources released would allow treatment of 759 to 1,293 new patients over 12 months, with the potential benefit of reduced waiting lists. CONCLUSIONS : The results show that incremental use of DXI is associated with significant economic advantages in both simulations, with estimated cost savings being directly proportional to its degree of market penetration.
- || dexamethasone / Generic mfg., Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study. (Pubmed Central) - Oct 3, 2020
The average annual eye-related medical cost of the DEX-implant group was significantly lower than that of the anti-VEGF group during the study period, which was mainly due to decreased utilisation of eye care-related injections. Further long-term studies are needed.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab. (Pubmed Central) - Oct 2, 2020
The addition of targeted PRP to areas of non-perfusion in a patient with DMO does not reduce the number of injections required in the first year. It seems most likely that local VEGF at the macula is the main cause of DMO.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Modeling Time Effects in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema - A Mixed Model Analysis of Real-World Data. (Pubmed Central) - Sep 30, 2020
Conclusions The treatment of DMO with VEGF inhibitors was efficacious and well-tolerated in this clinical practice setting. Maximizing patient involvement, addressing missed appointments due to unforeseen circumstances, and adopting a proactive approach will help ensure positive treatment outcomes for the majority of patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Drug utilization in patients treated with anti-VEGFs for diabetic macular edema (DME) in the UK (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1698;
Overall >59%, >27% of treated eyes had treatment free intervals ≥q12-, ≥q16-weeks during the first and second years after treatment initiation. However, in many of the cases extension by >12 weeks occurred only once (during the entire two-year period).
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anatomical, visual, and durability outcomes from the BOULEVARD phase 2 trial of faricimab for diabetic macular edema (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1692;
P2
Faricimab also demonstrated sustained efficacy with respect to disease reactivation and sustained retinal stability earlier than ranibizumab in the intent-to-treat population in a dose-dependent manner. The global phase 3 program to further investigate the efficacy and safety of faricimab is ongoing.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Optimization of the implant insertion procedure for the port delivery system with ranibizumab (PDS) in the ladder phase 2 trial (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1685;
P2, P3
Adherence to the optimized surgical methodologies is key to maximizing successful outcomes with these procedures. This includes careful conjunctival and Tenon’s capsule management during PDS implant insertion surgery as well as the specified angle approach and targeting technique during the refill-exchange procedure.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Retreatment interval pattern of ranibizumab and aflibercept treat-and-extend regimen in patients with neovascular age-related macular degeneration: Secondary results from the RIVAL study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1656;
Similar trends were observed in both RBZ and AFL treated patients who returned to a retreatment interval of 4 weeks or had their treatment intervals reduced by 2 weeks. Only few of the extended patients had a reduced treatment interval due to loss in VA alone which indicates that the T&E is a very effective clinical regimen allowing disease activity to dictate the intensity of treatment required.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment patterns in the United Kingdom and Western Europe at Year 1 in treatment-naïve neovascular age-related macular degeneration patients treated with ranibizumab: the LUMINOUS study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1647;
P=N/A
At Year 1, the mean gain in VA was 2.7 letters in the UK, which was numerically higher than in WE (0.7 letters). The variability in VA outcomes and treatment exposure could be due to different treatment practices in the UK and WE.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] STAIRWAY: impact of faricimab treatment on neovascular age-related macular degeneration (nAMD) lesions using different imaging modalities (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1635;
P2, P3
The effects observed on macular anatomy in STAIRWAY patients support the preclinical evidence indicating the potential of simultaneous Ang-2/VEGF-A neutralization for sustained vascular stability, reduced leakage, and anti-angiogenic effects. These data suggest that faricimab, through dual Ang-2/VEGF inhibition, may lead to sustained efficacy and offer durability of treatment effect.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intraocular pressure changes and VEGF inhibitor use in various retinal diseases - two-year real-world outcomes: data from the fight retinal blindness! Registry (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1622;
Mean IOP did not change significantly from baseline to 12 and 24 months in eyes receiving VEGF inhibitors, while clinically significant IOP elevations occurred in a small proportion of eyes. Aflibercept was associated with fewer clinically significant IOP elevations, whereas eyes with pre-existing glaucoma were at a higher risk.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy and safety of intravitreal ranibizumab in the treatment of diabetic macular oedema: four-year results from a real-world clinical practice (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1538;
Our results from real world clinical practice on diabetic macular oedema with ranibizumab showed desirable visual improvement and stability over 4 years, delivering a long term effective and safe treatment regimen. A small number of non-responders required switching to Aflibercept in Year-2 and appeared to achieve slightly higher VA gain at follow-up.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Outcomes of treatment with ranibizumab on a pro-re-nata strategy for diabetic macular oedema: 36-month real world evidence (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1534;
Significant and sustainable visual acuity gains were achieved from the first year of treatment, even with a PRN strategy and tolerance of some macular exudation. The treatment burden was decreasing during the course of the study for the good responders but there was need for alternative treatment for a subgroup of our patients.
- Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Idiopatic macular telangectasy type 1 (MacTel-1) different treatment approaches (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1532;
MacTel type 1 is a rare vascular disease, this makes the decision of an optimal treatment difficult since several modalities cannot be evaluated in a randomized controlled protocol, therefore, the treatment guidelines are not well defined.The focal laser proved to be a good treatment alternative. However, it is not without visual adverse effects.
- Lucentis (ranibizumab) / Roche, Novartis, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
[VIRTUAL] Fluocinolone acetonide intravitreal implant (ILUVIEN®) as the treatment for chronic macular oedema (MO) in retinal vein occlusions (RVO): case series of two-year follow-up (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1524;
The eyes needed only very few additional injections over the 2-year follow-up period. The only known adverse effect was varied period of intraocular pressure spike.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
[VIRTUAL] 36 months after ILUVIEN® (fluocinolone acetonide, FAc, 0.2μg/day) in eyes with persistent and recurrent diabetic macular edema: to reinject or not to reinject? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1509;
The eye that received a second ILUVIEN® implant at month 39 had visual and anatomical gains, maintained for at least another year.On the other hand, the case kept its macula dry, with absence of edema after almost 5 years, without requiring any additional reinjection. The multifactorial nature of DME is responsible for the need of an individualized treatment for DME and explains why some patients need a second ILUVIEN® after 3 years to achieve a successful outcome for the patient, while, in others, one ILUVIEN® can lead to sustained control of inflammation and, consequently, prevent the recurrence of edema, without need of reinjection.
- Lucentis (ranibizumab) / Roche, Novartis, fingolimod / Generic mfg., Novus Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Branch retinal venous occlusion in a fingolimod-treated patient: a case report (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1507;
It blocks the exit of lymphocytes from lymphatic tissue to the blood, protecting the central nervous system from lymphocytes attacking myelin. Fingolimod achieves that effect joining to esphingosine-1 phosphate receptors of lymphocytes.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema: 1 year follow-up (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1497;
Purpose: Evaluate the macular thickness and visual acuity after the treatment using aflibercept plus ranibizumab with dexamethasone intravitreal injection in diabetic macular edema€™s eyes... We can state through this study that the treatment of diabetic macular edema with anti-VEGF associated with corticosteroid has a greater benefit than the treatment with these single drugs, shown by optical coherence tomography.Visual acuity increased with the association of drugs regardless of which antiangiogenic drug used.
- [VIRTUAL] Healthcare resource use and costs comparison of managing diabetic macular edema with dexamethasone intravitreal implant, aflibercept and ranibizumab in treatment naïve patients: a French health economics study (INVICOST) (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1488;
This study did not consider the occurrence of cataract beyond 1 year. A multicenter study with a larger sample size would allow for better assessment of the potential variability of HCRU across centers, in particular, the frequency of IVI.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-phospholipid syndrome and retinal vein occlusion (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1468;
This case of combined BRVO and CRVO serves as a reminder to evaluate coagulation times and screening for APLA in patients with vaso-occlusive retinal disease, even if they are not free of conventional risk factors. Anti-coagulation therapy should be started, and the patient should be carefully followed up during the treatment period to prevent other serious complications and recurrent thrombosis.
- [VIRTUAL] Dexamethasone intravitreal implant: real-world outcomes of a 52-week follow-up in diabetic macular oedema and macular oedema secondary to retinal vein occlusions (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1467;
Despite the limited number of patients, our results are comparable to the larger multicentre studies. The benefits of switching are not limited to improving macular anatomy and visual acuity; our study effectively demonstrates the benefits of the use of dexamethasone implant with fewer treatment episodes.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A retrospective study of eyes with diabetic macular edema (DME) refractory to anti-VEGF treatment in a tertiary hospital in the United Kingdom (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1466;
This study highlights the burden of DME treatment being refractory to anti VEGF in a significant proportion of our cases along with the numerous visits made for their treatments.The management of these patients include switching between anti-VEGF treatments, increasing the frequency of injections and switching to another class of drugs e.g. intravitreal steroids. Furthermore, the current COVID 19 pandemic has placed further challenges on the healthcare system to provide a safe delivery of treatment to our patients.Although retrospective nature of the study and lack of electronic data recording limits its conclusions this study establishes DME becoming refractory over time (57% in 2.5 years) and a need for alternative or rescue treatment options after revising the definition for non-responsive / refractory cases.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Prognostic criteria determining the favorable and unfavorable course of myopic choroidal neovascularization (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1461;
Thus, based on the data of the comparative analysis, the prognostic criteria for the adverse course of mCNV and resistance to anti-VEGF therapy can be considered: the axial length of the eyeball is more than 28 mm; a critical decrease in the thickness of the choroid on average to 50.0 ± 2.7 microns; a subretinal neovascular membrane that forms according to type 3 of the pattern; the predominant change in the menstrual-ovarian cycle according to the type of amenorrhea and opsomenorrhea; a 2-fold increase in the concentration of lipoprotein (a) above the reference values; increased concentration of sex and pituitary hormones. The use of multidisciplinary approaches for this disease will increase the effectiveness of treatment and prevent the development of relapses of mCNV and clinically pronounced changes in the double eye.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intravitreal ranibizumab as rescue therapy after laser photocoagulation in retinopathy of prematurity (ROP) (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1453;
The use of multidisciplinary approaches for this disease will increase the effectiveness of treatment and prevent the development of relapses of mCNV and clinically pronounced changes in the double eye. IVR could be an option in patients with ROP in whom complete laser photocoagulation failed to control the disease.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Outcomes of ranibizumab injections for the treatment of DMO at the Royal Free Hospital (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1435;
In our sample, the overall ETDRS letter score gain at 12 months was +4.69 compared to +6.1 and +9 in RESTORE and DRCR.net studies respectively. The overall CRT gain was -109.9 compared to -118.7 and -101 in RESTORE and DRCR.net studies respectively.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Clinical assessment of surgical treatment of acute postoperative endophthalmitis (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1377;
An increase in cases of verification of methicillin-resistant staphylococcus strains causes some caution. Vancomycin - resistant strains were not detected.Emergency vitreoretinal surgery with intraviral administration of a combination of antibacterial drugs allows to restore visual function in acute postoperative endophthalmitis.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF in the treatment of choroidal neovascular membrane secondary to Stargardt’s disease (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1333;
On the basis of our findings, intravitreal anti-VEGF injection seems to induce total regression of CNV secondary to Stargardt´s disease so it must be considered in the treatment of this complication. Furthermore OCTA provides a useful approach for CNV`s diagnosis as well as for monitoring and evaluating the treatment of intravitreal anti-VEGF so it could be a useful tool in clinical practice.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF therapy for subfoveal choroidal neovascularization in childhood (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1236;
Intravitreal ranibizumab was safe and effective in pediatric cases with CNV. Increase in visual acuity was maintained in long term with few injections.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effect of different lens status on intraocular pressure elevation in patients treated with anti-vascular endothelial growth factor injections (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1233;
Nd:YAG capsulotomy appears to be a risk factor for sustained IOP elevation in patients receiving intravitreal anti-VEGF injections. This finding has important implications given the growing use of anti-VEGF treatment and the irreversible effects of elevated IOP.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Macular star and capillary macroaneurysm in MacTel type-1: value of the study with multimodal imaging (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1140;
The multimodal imaging study contributes significantly to a better understanding and diagnosis of different pathologies of the retina. This case enhances the use of laser photocoagulation as the standard treatment for mactel type 1 obtaining in this particular case poor results with intravitreal corticosteroids or intravitreal anti-vascular endothelial growth factor agents.
- dexamethasone / Generic mfg., Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Sequential filtration surgery secondary to bilateral intravitreal dexamethasone-induced refractory glaucoma (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1101;
Repetitive implant injections may increase the need for surgical management for elevated IOP. ExPress GFD implantation can be chosen safely in such cases, over trabeculectomy, since it is a less invasive procedure.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Submacular injection of ranibizumab as a new surgical treatment for refractory diabetic macular edema (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1090;
ExPress GFD implantation can be chosen safely in such cases, over trabeculectomy, since it is a less invasive procedure. This novel surgical procedure of vitrectomy with ILM peeling with a subretinal injection of ranibizumab is effective in cases of refractory DME.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Evaluating the unmet needs of AMD patients and their correlation with OCT imaging: a survey (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1088;
We noted a correlation between dissatisfaction and response to treatment on OCT. Nevertheless, the majority of the patients are satisfied with the quality of care we provide.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Is there a relationship between retinal pigment epithelial atrophy and anti-VEGF injections of aflibercept or ranibizumab? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1084;
Some factors may have limited the quality of the results. For example, do not specify whether the type of therapy is monthly, quarterly, pro-Renata, or treat & extend, and whether the drug delivery system develops GA instead of enrolling patients with atrophy already present.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Retinal fluid assessment and control in neovascular age related macular degeneration (nAMD): online medical education significantly improves ophthalmologists’ knowledge, competence and confidence (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1083;
The activity also suggested a need for new treatment options to achieve the treatment goal of drying the retina in more patients. A high unmet need still remains for further education on nAMD disease assessment and utilizing evolving technologies.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] What happens after stopping the T&E regimen in neovascular AMD? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1073;
A high unmet need still remains for further education on nAMD disease assessment and utilizing evolving technologies. The decision to stop treating a patient who has responded well to treatment should be evaluated in some cases, especially in type 3 neovascular lesions that have already lost central vision in the other eye due to this disease.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Recurrent RPE apertures in a patient with CNVM: a continuum? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1068;
Development of CNVM and RPE aperture in AMD may indicate a continuum with RPE aperture indicating atrophy while the development of CNV being a complication of a breach in RPE-Bruch’s complex. This case also illuminates the fact that intact ellipsoid zone and ELM is more important for visual acuity than RPE .
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Subretinal fibrosis in nAMD in the era of anti-VEGF treatment (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1064;
It is driven mostly by myofibroblasts, although many types of cells may contribute to this process. The occurrence of subretinal fibrosis during the treatment of nAMD is an indicator of poor visual acuity in those patients.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effect of anti-VEGF treatment drug and regimen on new and recurrent submacular haemorrhage secondary to neovascular age-related macular degeneration: findings from the IVAN randomised trial (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1061;
Incidence of new SMH following treatment initiation was associated with history of TIA and presence of GA at baseline. Incidence of both new and recurrent SMH were associated with an as-needed treatment regimen whereas drug choice had no significant influence.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Review of UK real-world outcomes of anti-VEGF therapy for neovascular AMD (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1060;
Outcomes have improved as more proactive treatment regimens have been adopted with more frequent intravitreal injections. There is an unmet need for longer acting anti-VEGF therapies that would reduce the treatment burden for patients, carers and healthcare systems and make replication of impressive clinical trial results possible in the NHS.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Risk factors and outcomes associated with submacular haemorrhage secondary to neovascular age-related macular degeneration: findings from the IVAN randomised trial (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1059;
Approximately 50% of the IVAN trial patients had SMH at baseline and despite most of these being small in size, presence of SMH consistently reduced the initial VA by a mean of a line of vision. The occurrence of baseline SMH was associated with older age and the presence of retinal cysts.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Short-term outcomes following “switching” to monthly ranibizumab in the patients with neovascular age-related macular degeneration showing insufficient response to bimonthly aflibercept (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1055;
Switching to monthly ranibizumab in the patients with nAMD showing insufficient response to bimonthly aflibercept led to an immediate anatomical improvement especially in the first month after switching. After continued monthly ranibizumab treatment, in some patients, small amount of SRF tended to recur after 2 months after switching.